P.A.S. SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do P.a.s. Sodium patents expire, and when can generic versions of P.a.s. Sodium launch?
P.a.s. Sodium is a drug marketed by Century Pharms and is included in one NDA.
The generic ingredient in P.A.S. SODIUM is aminosalicylate sodium. There are three drug master file entries for this compound. Additional details are available on the aminosalicylate sodium profile page.
Summary for P.A.S. SODIUM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Clinical Trials: | 3,629 |
Patent Applications: | 6 |
Formulation / Manufacturing: | see details |
DailyMed Link: | P.A.S. SODIUM at DailyMed |
Recent Clinical Trials for P.A.S. SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sahlgrenska University Hospital, Sweden | Phase 4 |
Harvard Medical School (HMS and HSDM) | Phase 4 |
Swedish Heart Lung Foundation | Phase 4 |
US Patents and Regulatory Information for P.A.S. SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Century Pharms | P.A.S. SODIUM | aminosalicylate sodium | POWDER;ORAL | 080947-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |